Licogliflozin

Licogliflozin

Legal status
Legal status	Investigational
Identifiers
IUPAC name (2S,3R,4R,5S,6R)-2-{3-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-ethylphenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
CAS Number	1291094-73-9  Y
PubChem CID	52913524
UNII	57J06X6EI0
Chemical and physical data
Formula	C23H28O7
Molar mass	416.470 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2
InChI InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1 Key:XFJAMQQAAMJFGB-ZQGJOIPISA-N

Licogliflozin is a drug which acts as an SGLT2 inhibitor. It was originally developed as a potential treatment for obesity, ^[1] but has also been investigated for other applications such as treating symptoms of polycystic ovary syndrome and nonalcoholic steatohepatitis. ^{[2] [3]}

References

1. Zaki AM, Abo-Elnour DE, Abdalla YE, Hassan RY, Salama MK, Elboraay T, et al. (November 2022). "Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials". Diabetes & Metabolic Syndrome. 16 (11) 102657. doi:10.1016/j.dsx.2022.102657. PMID   36335885.
2. Tan S, Ignatenko S, Wagner F, Dokras A, Seufert J, Zwanziger D, et al. (November 2021). "Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial". Diabetes, Obesity & Metabolism. 23 (11): 2595–2599. doi: 10.1111/dom.14495 . PMID   34263971.
3. Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, et al. (July 2022). "Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study". Nature Medicine. 28 (7): 1432–1438. doi:10.1038/s41591-022-01861-9. PMC   10061496 . PMID   35725922.